AU2019338236B2 - A GABAA receptor ligand - Google Patents
A GABAA receptor ligand Download PDFInfo
- Publication number
- AU2019338236B2 AU2019338236B2 AU2019338236A AU2019338236A AU2019338236B2 AU 2019338236 B2 AU2019338236 B2 AU 2019338236B2 AU 2019338236 A AU2019338236 A AU 2019338236A AU 2019338236 A AU2019338236 A AU 2019338236A AU 2019338236 B2 AU2019338236 B2 AU 2019338236B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- itch
- treatment
- vehicle
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18194297 | 2018-09-13 | ||
| EP18194297.0 | 2018-09-13 | ||
| PCT/EP2019/074465 WO2020053377A1 (en) | 2018-09-13 | 2019-09-13 | A gabaa receptor ligand |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019338236A1 AU2019338236A1 (en) | 2021-05-20 |
| AU2019338236B2 true AU2019338236B2 (en) | 2025-01-09 |
Family
ID=63579205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019338236A Active AU2019338236B2 (en) | 2018-09-13 | 2019-09-13 | A GABAA receptor ligand |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11396510B2 (enExample) |
| EP (1) | EP3849976B1 (enExample) |
| JP (1) | JP7353663B2 (enExample) |
| KR (1) | KR102712565B1 (enExample) |
| CN (1) | CN112714765B (enExample) |
| AU (1) | AU2019338236B2 (enExample) |
| BR (1) | BR112021004661A2 (enExample) |
| CA (1) | CA3110283A1 (enExample) |
| DK (1) | DK3849976T3 (enExample) |
| EA (1) | EA202190717A1 (enExample) |
| ES (1) | ES2935705T3 (enExample) |
| FI (1) | FI3849976T3 (enExample) |
| HR (1) | HRP20230067T1 (enExample) |
| HU (1) | HUE060943T2 (enExample) |
| IL (1) | IL281335B2 (enExample) |
| LT (1) | LT3849976T (enExample) |
| MX (1) | MX2021003010A (enExample) |
| PH (1) | PH12021550299A1 (enExample) |
| PL (1) | PL3849976T3 (enExample) |
| PT (1) | PT3849976T (enExample) |
| SG (1) | SG11202101360VA (enExample) |
| SI (1) | SI3849976T1 (enExample) |
| WO (1) | WO2020053377A1 (enExample) |
| ZA (1) | ZA202100976B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022219046A1 (en) | 2021-04-16 | 2022-10-20 | Saniona A/S | A gaba receptor modulator for use in the treatment of pain |
| WO2025056753A1 (en) * | 2023-09-15 | 2025-03-20 | Saniona A/S | A gaba receptor modulator for treating disorders associated with sleep spindle deficits |
| WO2025056751A1 (en) * | 2023-09-15 | 2025-03-20 | Saniona A/S | A gaba receptor modulator for use in the treatment of absence seizures |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007110374A1 (en) * | 2006-03-24 | 2007-10-04 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU675484B2 (en) | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| GB9702524D0 (en) | 1997-02-07 | 1997-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| ATE284403T1 (de) | 1999-01-27 | 2004-12-15 | Merck Sharp & Dohme | Triazolopyridazinderivate als liganden für gaba- rezeptoren |
| GB9921150D0 (en) * | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208394D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic agents |
| GB0208392D0 (en) | 2002-04-11 | 2002-05-22 | Merck Sharp & Dohme | Therapeutic compounds |
| GB0212048D0 (en) * | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004087690A2 (en) | 2003-04-03 | 2004-10-14 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| TW201029986A (en) | 2008-11-14 | 2010-08-16 | Neurosearch As | Novel compounds |
| MX388862B (es) | 2016-01-27 | 2025-03-20 | Univ Zuerich | Uso de moduladores de receptores de gabaa para el tratamiento de picor. |
-
2019
- 2019-09-13 LT LTEPPCT/EP2019/074465T patent/LT3849976T/lt unknown
- 2019-09-13 ES ES19765747T patent/ES2935705T3/es active Active
- 2019-09-13 HR HRP20230067TT patent/HRP20230067T1/hr unknown
- 2019-09-13 PT PT197657471T patent/PT3849976T/pt unknown
- 2019-09-13 SI SI201930443T patent/SI3849976T1/sl unknown
- 2019-09-13 MX MX2021003010A patent/MX2021003010A/es unknown
- 2019-09-13 AU AU2019338236A patent/AU2019338236B2/en active Active
- 2019-09-13 US US17/272,971 patent/US11396510B2/en active Active
- 2019-09-13 WO PCT/EP2019/074465 patent/WO2020053377A1/en not_active Ceased
- 2019-09-13 EA EA202190717A patent/EA202190717A1/ru unknown
- 2019-09-13 SG SG11202101360VA patent/SG11202101360VA/en unknown
- 2019-09-13 IL IL281335A patent/IL281335B2/en unknown
- 2019-09-13 HU HUE19765747A patent/HUE060943T2/hu unknown
- 2019-09-13 BR BR112021004661-5A patent/BR112021004661A2/pt unknown
- 2019-09-13 KR KR1020217006185A patent/KR102712565B1/ko active Active
- 2019-09-13 DK DK19765747.1T patent/DK3849976T3/da active
- 2019-09-13 JP JP2021514324A patent/JP7353663B2/ja active Active
- 2019-09-13 CA CA3110283A patent/CA3110283A1/en active Pending
- 2019-09-13 FI FIEP19765747.1T patent/FI3849976T3/fi active
- 2019-09-13 PL PL19765747.1T patent/PL3849976T3/pl unknown
- 2019-09-13 EP EP19765747.1A patent/EP3849976B1/en active Active
- 2019-09-13 CN CN201980059446.2A patent/CN112714765B/zh active Active
-
2021
- 2021-02-10 PH PH12021550299A patent/PH12021550299A1/en unknown
- 2021-02-12 ZA ZA2021/00976A patent/ZA202100976B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007110374A1 (en) * | 2006-03-24 | 2007-10-04 | Neurosearch A/S | Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3849976B1 (en) | 2022-10-26 |
| KR102712565B1 (ko) | 2024-10-02 |
| JP7353663B2 (ja) | 2023-10-02 |
| JP2022500445A (ja) | 2022-01-04 |
| BR112021004661A2 (pt) | 2021-06-01 |
| EP3849976A1 (en) | 2021-07-21 |
| EA202190717A1 (ru) | 2021-09-22 |
| LT3849976T (lt) | 2023-02-10 |
| ZA202100976B (en) | 2022-08-31 |
| US20210332042A1 (en) | 2021-10-28 |
| DK3849976T3 (da) | 2023-01-23 |
| SG11202101360VA (en) | 2021-03-30 |
| FI3849976T3 (fi) | 2023-02-19 |
| SI3849976T1 (sl) | 2023-03-31 |
| IL281335B1 (en) | 2024-03-01 |
| HUE060943T2 (hu) | 2023-04-28 |
| AU2019338236A1 (en) | 2021-05-20 |
| IL281335A (en) | 2021-04-29 |
| HRP20230067T1 (hr) | 2023-03-17 |
| US11396510B2 (en) | 2022-07-26 |
| KR20210061338A (ko) | 2021-05-27 |
| PL3849976T3 (pl) | 2023-02-27 |
| ES2935705T3 (es) | 2023-03-09 |
| CN112714765A (zh) | 2021-04-27 |
| PT3849976T (pt) | 2023-01-13 |
| PH12021550299A1 (en) | 2021-10-25 |
| MX2021003010A (es) | 2021-05-27 |
| WO2020053377A1 (en) | 2020-03-19 |
| IL281335B2 (en) | 2024-07-01 |
| CA3110283A1 (en) | 2020-03-19 |
| CN112714765B (zh) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102049048B (zh) | 治疗或预防的方法 | |
| EA021303B1 (ru) | Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста | |
| CN111655669A (zh) | 治疗包括运动神经元疾病的神经紊乱的组合物和方法 | |
| AU2019338236B2 (en) | A GABAA receptor ligand | |
| JP2016525547A (ja) | 神経保護性の二環式化合物ならびに自閉症スペクトラム障害および神経発達障害の治療におけるそれらの使用方法 | |
| KR102015484B1 (ko) | 순수한 5-ht6 수용체 길항제와 아세틸콜린에스테라제 저해제의 조합물 | |
| EP1183025B1 (en) | Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders | |
| JP6606298B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ | |
| JP6629464B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ | |
| KR20200019747A (ko) | 순수한 5-ht6 수용체 길항제의 신규 용도 | |
| WO2018237174A2 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
| HK40057209B (en) | A gabaa receptor ligand | |
| HK40057209A (en) | A gabaa receptor ligand | |
| EP2588109A1 (en) | Use of kynurenic acid amide derivatives for the treatment of huntington's disease | |
| EA042675B1 (ru) | Лиганд рецептора гамк-а | |
| AU2015363757B2 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| JPH10236963A (ja) | カルシウムチャンネル拮抗剤 | |
| JP2023046235A (ja) | 医薬組成物及びｓｔａｔ３のリン酸化阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |